格隆汇1月28日｜塞力医疗（维权）公告称，减持计划实施前，上海盎泽持有公司1210.04万股，占总股 本5.76%。2025年10月1日，上海盎泽披露减持计划，拟在2025年10月30日至2026年1月29日减持不超 420.28万股，占总股本2%。截至2026年1月28日，上海盎泽已完成减持，通过集中竞价和大宗交易合计 减持309.12万股，占截至2026年1月20日总股本的1.47%，减持总金额6522.63万元。减持后，上海盎泽 剩余持股900.92万股，占比4.29%。 ...

| 成交量(万 | 成交金额(万 | 成交价格 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | | 股) | 元) | (元) | | | | | | | 方正证券股份有限公司湖北分 | 财通证券股份有限公司上海分 | | 100.00 | 2200.00 | 22.00 | | | | | | | 公司 | 公司 | （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨 询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保 证和承诺。 塞力医疗01月28日大宗交易平台共发生1笔成交，合计成交量100.00万股，成交金额2200.00万元。成交 价格平均为22.00元，相对今日收盘价折价5.54%。 01月28日塞力医疗大宗交易一览 ...

| 交易日期 | | 券代码 成 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 奥出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | | 026-01-28 | 塞力医疗 | 603716 22 22 2200 | 100 | 态焉嫣然劈堡有限 | 髮槽里킬劈纹葫芦 | Ka | 1月28日，塞力医疗大宗交易成交100万股，成交额2200万元，占当日总成交额的5.55%，成交价22元， 较市场收盘价23.29元折价5.54%。 ...

格隆汇1月28日丨塞力医疗(603716.SH)在投资者互动平台表示，目前公司暂无尼帕病毒病原学检测试剂/ 仪器或治疗药物储备，也暂无相关产品代理。我们的布局重点在"高危急性感染的早期识别与预警"能 力：基于战略投资并引进的Inflammatix TriVerity急性感染与脓毒症检测，可在症状极早期通过mRNA转 录组信号实现感染类型判断（病毒/细菌/非感染）及重症/脓毒症风险分层。对尼帕这类疑似病例， TriVerity可作为急诊/发热门诊的早期预警与分诊升级工具，提示更高等级隔离与监护、支持更快启动确 诊检测与救治流程，最终确诊仍需病原学检测配合。 （原标题：塞力医疗(603716.SH)：暂无尼帕病毒病原学检测试剂/仪器或治疗药物储备） ...

Core Viewpoint - The company currently does not have any Nipah virus-related testing reagents, instruments, or treatment drugs in its inventory, nor does it have any products for agency sales. The focus is on early identification and warning capabilities for high-risk acute infections through the Inflammatix TriVerity™ system, which can assist in early triage and monitoring for suspected cases of Nipah virus [1]. Group 1 - The company received an inquiry regarding its preparedness for the Nipah virus outbreak in West Bengal, India, which has affected several healthcare workers [1]. - The company confirmed that it does not possess any Nipah virus-related testing reagents or treatment options at this time [1]. - The company's strategic focus is on early identification and warning for high-risk acute infections, utilizing the Inflammatix TriVerity™ system for early infection type determination and risk stratification [1]. Group 2 - The Inflammatix TriVerity™ system can provide early warning and triage support in emergency settings for suspected cases, facilitating quicker diagnosis and treatment processes [1]. - The company emphasizes that while TriVerity™ can assist in early detection, final confirmation still requires pathogen detection methods [1].

格隆汇1月28日丨塞力医疗(603716.SH)在投资者互动平台表示，目前公司暂无尼帕病毒病原学检测试剂/ 仪器或治疗药物储备，也暂无相关产品代理。我们的布局重点在"高危急性感染的早期识别与预警"能 力：基于战略投资并引进的Inflammatix TriVerity急性感染与脓毒症检测，可在症状极早期通过mRNA转 录组信号实现感染类型判断（病毒/细菌/非感染）及重症/脓毒症风险分层。对尼帕这类疑似病例， TriVerity可作为急诊/发热门诊的早期预警与分诊升级工具，提示更高等级隔离与监护、支持更快启动确 诊检测与救治流程，最终确诊仍需病原学检测配合。 ...

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

Group 1 - The core point of the article is that Sely Medical reported a total of 105,076 shareholders as of January 10, 2026 [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

Core Viewpoint - The company, Sely Medical, announced the convening of its first extraordinary shareholders' meeting on January 7, 2026, to discuss the proposal for expanding its business scope and corresponding amendments [2] Group 1 - The company has recently completed the industrial and commercial change of its business scope and the filing procedures for its Articles of Association [2] - The company has obtained a new business license issued by the Administrative Approval Bureau of the Dongxihu District in Wuhan [2]